通过免疫组织学检测到的骨髓浆细胞微聚集体可预测骨髓瘤患者在大剂量治疗后微小病变时的早期复发。
Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma.
作者信息
Wei Andrew, Westerman David, Feleppa Frank, Trivett Melanie, Juneja Surender
出版信息
Haematologica. 2005 Aug;90(8):1147-9.
PMID:16079123
Abstract
Plasma cell microaggregates detected by CD138 immunohistology were demonstrated in 22% of patients achieving morphologic remission 3 months after high-dose therapy for myeloma. Microaggregates were predictive of earlier disease progression, indicating that immunohistology may represent a useful tool in the assessment of minimal disease in patients after high-dose therapy for myeloma.
摘要
通过CD138免疫组织化学检测到的浆细胞微聚集体在接受骨髓瘤大剂量治疗3个月后达到形态学缓解的患者中占22%。微聚集体可预测疾病更早进展，这表明免疫组织化学可能是评估骨髓瘤大剂量治疗后患者微小疾病的有用工具。
Zotero 插件